Market Place
Sourcing Support
Quoin Pharma Corporate Update & Announce Q3 2024 Financial Results
07 Nov 2024 //
GLOBENEWSWIRE
Quoin Pharma Initiates Pediatric Testing for Netherton Syndrome
05 Nov 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals to Report Q3 2024 Results on Nov 7
31 Oct 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Expands International Trials For Netherton
22 Oct 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Insider Share Purchases
09 Sep 2024 //
GLOBENEWSWIRE
Quoin Pharma Provides Update And Announces Q2 2024 Results
08 Aug 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
06 Aug 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals To Announce Q2 2024 Results On August 8
01 Aug 2024 //
GLOBENEWSWIRE
Quoin Pharma Announces International Expansion of Ongoing Clinical Trials
27 Jun 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals to Sponsor FIRST 2024 National Conference
25 Jun 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Signs Research Agreement With UCC Ireland
12 Jun 2024 //
GLOBENEWSWIRE
Quoin Pharma Q1 2024 Results And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Quoin Pharma Q1 2024 Results On May 9
02 May 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering
05 Mar 2024 //
GLOBENEWSWIRE
Quoin Announces Clearance to Recruit Subjects into Netherton Syndrome Studies
04 Mar 2024 //
GLOBENEWSWIRE
Quoin Files Patent Applications for Novel Netherton Syndrome Product
08 Feb 2024 //
GLOBENEWSWIRE
Quoin Announces FDA Clearance of Clinical Optimization Plan for QRX003
13 Dec 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results
03 Nov 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Data from Open-Label in Netherton Syndrome
24 Oct 2023 //
GLOBENEWSWIRE
Quoin Announces Additional Positive Data in Netherton Syndrome
24 Oct 2023 //
GLOBENEWSWIRE
Quoin Provides Corporate Update and Announces Q2 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results
27 Jul 2023 //
GLOBENEWSWIRE
Quoin Pharma Announces 50% Enrollment in Open Label Netherton Syndrome Trial
24 May 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Provides Corporate Update and Announces 1Q 2023 FYR
08 May 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces 1Q 2023 FYR and Corporate Update Conference Call
02 May 2023 //
GLOBENEWSWIRE
Quoin Doses First Patient in Open Label Netherton Syndrome Clinical Trial
21 Mar 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call
02 Mar 2023 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
22 Feb 2023 //
GLOBENEWSWIRE
Quoin Announces Dosing of First Patient in Trial in Netherton Syndrome
13 Dec 2022 //
GLOBENEWSWIRE
Quoin Announces Updated Timing of Q3 2022 Corporate Update Conference
03 Nov 2022 //
GLOBENEWSWIRE
Quoin Pharmaceuticals to Report 3Q 2022 FYR and Provide Corporate Update on Nov
01 Nov 2022 //
GLOBENEWSWIRE
Quoin Announces Plans to Initiate a Second Trial in Netherton Syndrome Patients
18 Oct 2022 //
GLOBENEWSWIRE
Quoin Establishes Patient Specific Website for Ongoing Netherton Syndrome
13 Sep 2022 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Second Quarter 2022 Financial Results
18 Aug 2022 //
GLOBENEWSWIRE
Quoin Pharmaceuticals to Report Q2 2022 Result and Provide Corporate Update
11 Aug 2022 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering
09 Aug 2022 //
GLOBENEWSWIRE
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering
05 Aug 2022 //
GLOBENEWSWIRE
Quoin Pharma Announces Receipt of Constructive Advice from EMA for QRX003
28 Jul 2022 //
GLOBENEWSWIRE
Endo Announces Agreement for Quoin Pharmaceuticals` QRX003 in Canada
15 Jul 2022 //
PRNEWSWIRE
Quoin Pharma Opens First Clinical Site for Netherton Syndrome Study
06 Jul 2022 //
GLOBENEWSWIRE
Quoin Pharma Announces Agreement with Leading Rare Disease Co.
15 Jun 2022 //
GLOBENEWSWIRE
Quoin Pharma Receives Nasdaq Deficiency Notice
15 Jun 2022 //
GLOBENEWSWIRE
Quoin Pharma Enters Exclusive Research Agreement for Scleroderma
23 May 2022 //
GLOBENEWSWIRE
Sienna says March Dividend
15 Mar 2022 //
GLOBENEWSWIRE
Quoin Pharma Submits Scientific Advice Briefing Document to EMA for QRX003
10 Mar 2022 //
GLOBENEWSWIRE
Quoin Pharma Extends Exclusive Distribution Agreement with ER-Kim for QRX003
01 Mar 2022 //
GLOBENEWSWIRE
Quoin Pharma Signs Exclusive Distribution Agreement with Neopharm for QRX003
17 Feb 2022 //
GLOBENEWSWIRE
Quoin Pharma Signs Exclusive Distribution Agreement with ER-Kim for QRX003
10 Feb 2022 //
GLOBENEWSWIRE
